Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral vinorelbine plus capecitabine for HER2-negative advanced breast cancer
ChiCTR1900023851Phase 4Recruiting
- Sponsor
- Hubei Cancer Hospital
- Start
- Jul 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vinorelbine and capecitabine in breast cancer (2 arms), sponsored by Hubei Cancer Hospital. Primary endpoint: Progression-free survival. Started Jul 2019; status: recruiting.
02
Drugs
vinorelbinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900023851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023851.